Alzamend Neuro, Inc.


What is Alzheimer's disease?

We invest in innovation.

Through the licensing of promising intellectual property from internationally recognized organizations and institutions:

- Moving licensed technology forward toward commercialization;
- And the support of ongoing research Alzamend Neuro strives to help move the battle against Alzheimer's forward.

On December 8th, 2016 Alzamend Neuro became the first biotech company to receive a letter of qualification for its Reg. A+ Tier II Offering by the SEC to raise up to $50 million dollars. Alzamend Neuro continues to secure capital through traditional as well as innovative channels.

Join Alzamend in its quest to "Making Alzheimer's just a memory."



  • 14 million

    People will have Alzheimer's by 2050 if a cure is not found.

  • 3 million

    People age 85 and older will be afflicted by Alzheimer's

  • 88 million

    People will have Alzheimer's by 2050 if a cure is not found.

  • 6th

    Leading cause of death in the U.S. - Alzheimers

  • $277 bn

    The estimated cost of caring for Alzheimer's patients in 2017

  • 1-in-10

    Americans over age 65 afflicted with Alzheimer's disease

  • 5.7 million

    Americans currently living with the Alzheimer's disease

  • 1-in-3

    People over age 65 or older will have AD by 2050

  • Women

    Are 2-and-half times more likely than men to have Alzheimer's Disease

About Alzamend Neuro, Inc.

Alzamend Neuro is currently working to transition two biotechnologies from the research and pre-clinical stage at the University of South Florida Health Byrd Alzheimer's Institute into the clinical stage and towards full commercialization. Alzamend Neuro has licensed both a patented mutant peptide for use as an immunotherapeutic treatment or vaccine and a lithium/proline based co-crystal therapy that may greatly reduce or eliminate the symptoms of agitation and memory loss for early to moderate stage patients.

Latest Updates

  • Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals

    Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory application and oversight efforts including the successful filing of a FDA IND application and resulting in FDA approval to conduct a First Stage Clinical Trial for CAO22W. FULL PRESS RELEASE

  • USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders

    TAMPA, Fla., January 19, 2017 -- Alzamend Neuro™ has licensed the USF treatment to help advance commercialization. A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc. Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute, has focused his research on peptides for use as a vaccine for Alzheimer’s disease and other neurological diseases. Dr. Cao has developed an antigen activated immune cell-based vaccine that shows promise in helping combat nervous system dysfunctions in Alzheimer’s disease. Research has shown that the therapeutic vaccine can target the toxic protein in the brain and fix the impaired immune system in several Alzheimer’s mouse models. “Our research team has developed a therapeutic vaccine that can both combat the disease and improve the immune system,” Cao said. “The most recent results have proved that such therapy can improve memory and avoid an unwanted vaccine associated reaction in a mouse model, so it could be a very promising therapeutic for Alzheimer’s disease patients.” FULL ARTICLE

  • Alzamend Neuro™ Announces TV Icon Willie Aames as International Spokesperson

    SALT LAKE CITY, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today Willie Aames will serve as its International Spokesperson while joining the team as Creative Advisor. The Company stated that with its recent launch of its Regulation A+ Tier II Offering online at™, it looks forward to the many contributions, inspiration and leadership that Aames will provide. With the Company’s campaign targeted to raise $50MM in new equity capital in less than a full year and able to take investment immediately, the addition of Aames is strategic and notable. On December 8, 2016, the Company was notified by the SEC that it had qualified its Form 1-A Application allowing the Company to move forward with the Offering which will leverage the key component of the Reg. A+ Tier II rules which allow for the solicitation of the general public as well as traditional investors and financial institutions.

    Photos accompanying this announcement are available at


    A video accompanying this announcement is available at

    Although Willie Aames has starred in over 22 network series, Aames is best known worldwide for playing the iconic “Tommy Bradford” on the 1970s television series "Eight Is Enough" and Scott Baio’s heartwarming wingman “Buddy Lembeck" on the 1980s television hit series “Charles in Charge.” Aames also went on to star in 6 feature films. During the 1990s and through 2008 Aames developed his marketing skills making a name for himself as an award-winning, platinum-selling writer, producer and director. During this time, Aames successfully developed strategies, scripts and marketing plans for a myriad of companies including Fortune 500 titans Sprint, Northwest Airlines, Marion Labs and Helzberg Diamonds, a Berkshire Hathaway company. Aames also served as executive vice president of Pamplin Communications where he successfully developed several children's shows that became "sell through product" for Sony Wonder, Walmart and Toys"R"Us distribution channels.

  • Licenses Patented Alzheimer's Vaccine

    The University of South Florida was granted a patent related to this technology (USPTO # 8,188,046) in 2012, and this patent is exclusively licensed to Alzamend Neuro, a Utah-based pharmaceutical technology company that is dedicated to finding a prevention, treatment and cure for Alzheimer’s disease. The company’s goal is to move this technology out of the research and preclinical stage and into a path toward commercialization.

  • BioFlorida 2016

    Alzamend Neuro, Inc. CEO, Phil Mansour, will present as a part of a panel of on December 12th atBio Florida 2016, in Jacksonville, Florida, on the process, pros and cons of Reg A+.